Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial

Abstract Borayflo Haemostatic matrix is a new absorbable hemostatic gelatin matrix which can be used for intraoperative assisted hemostasis. In a prospective, multicenter, non-inferiority, randomized controlled trial, a total of 354 subjects were recruited from the departments of hepatobiliary surge...

Full description

Saved in:
Bibliographic Details
Main Authors: Peng Luo, Qi Lai, Li Xu, Zhenzhong Chen, Runsheng Guo, Banglin Xie, Ping Yi, Zhiying Yang, Bin Zhang
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-024-77487-3
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846171878952009728
author Peng Luo
Qi Lai
Li Xu
Zhenzhong Chen
Runsheng Guo
Banglin Xie
Ping Yi
Zhiying Yang
Bin Zhang
author_facet Peng Luo
Qi Lai
Li Xu
Zhenzhong Chen
Runsheng Guo
Banglin Xie
Ping Yi
Zhiying Yang
Bin Zhang
author_sort Peng Luo
collection DOAJ
description Abstract Borayflo Haemostatic matrix is a new absorbable hemostatic gelatin matrix which can be used for intraoperative assisted hemostasis. In a prospective, multicenter, non-inferiority, randomized controlled trial, a total of 354 subjects were recruited from the departments of hepatobiliary surgery, obstetrics and gynaecology and orthopaedics of 4 hospitals and randomly allocated to test group (Borayflo Haemostatic matrix) or control group (Surgiflo Haemostatic matrix) in a 1:1 ratio. In the modified intention-to-treat population, 163 (93.14%) of 175 subjects in the test group versus 167 (94.89%) of 176 subjects in the control group successfully achieved hemostasis within 5 min (P > 0.05). Non-inferiority for effective rates of hemostasis at 5 min to Surgiflo Haemostatic matrix was shown in the study (treatment difference: -1.74% [95%CI, -6.70–3.22%] for modified intention-to-treat population). In terms of efficacy and safety, the new hemostatic gelatin matrix (Borayflo Haemostatic matrix) is equivalent to Surgiflo Haemostatic matrix. There was no significant difference in the incidence of AEs or SAEs between the test and control groups(P > 0.05). In addition, Borayflo Haemostatic matrix is a domestically produced haemostatic gelatin product, an advantage that will reduce the cost of surgical haemostasis for Chinese patients.
format Article
id doaj-art-493f40a2d2a94553b9c9b2ba6923e301
institution Kabale University
issn 2045-2322
language English
publishDate 2024-11-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-493f40a2d2a94553b9c9b2ba6923e3012024-11-10T12:27:13ZengNature PortfolioScientific Reports2045-23222024-11-0114111210.1038/s41598-024-77487-3Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trialPeng Luo0Qi Lai1Li Xu2Zhenzhong Chen3Runsheng Guo4Banglin Xie5Ping Yi6Zhiying Yang7Bin Zhang8Orthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Hepatic-Biliary-Pancreatic Surgery, China-Japan Friendship HospitalDepartment of Orthopedics, Lishui Municipal Central HospitalOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityDepartment of Spine Surgery, China-Japan Friendship HospitalDepartment of Hepatic-Biliary-Pancreatic Surgery, China-Japan Friendship HospitalOrthopedic Hospital, The First Affiliated Hospital, Jiangxi Medical College, Nanchang UniversityAbstract Borayflo Haemostatic matrix is a new absorbable hemostatic gelatin matrix which can be used for intraoperative assisted hemostasis. In a prospective, multicenter, non-inferiority, randomized controlled trial, a total of 354 subjects were recruited from the departments of hepatobiliary surgery, obstetrics and gynaecology and orthopaedics of 4 hospitals and randomly allocated to test group (Borayflo Haemostatic matrix) or control group (Surgiflo Haemostatic matrix) in a 1:1 ratio. In the modified intention-to-treat population, 163 (93.14%) of 175 subjects in the test group versus 167 (94.89%) of 176 subjects in the control group successfully achieved hemostasis within 5 min (P > 0.05). Non-inferiority for effective rates of hemostasis at 5 min to Surgiflo Haemostatic matrix was shown in the study (treatment difference: -1.74% [95%CI, -6.70–3.22%] for modified intention-to-treat population). In terms of efficacy and safety, the new hemostatic gelatin matrix (Borayflo Haemostatic matrix) is equivalent to Surgiflo Haemostatic matrix. There was no significant difference in the incidence of AEs or SAEs between the test and control groups(P > 0.05). In addition, Borayflo Haemostatic matrix is a domestically produced haemostatic gelatin product, an advantage that will reduce the cost of surgical haemostasis for Chinese patients.https://doi.org/10.1038/s41598-024-77487-3
spellingShingle Peng Luo
Qi Lai
Li Xu
Zhenzhong Chen
Runsheng Guo
Banglin Xie
Ping Yi
Zhiying Yang
Bin Zhang
Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
Scientific Reports
title Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
title_full Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
title_fullStr Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
title_full_unstemmed Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
title_short Efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis: a prospective, randomized controlled trial
title_sort efficacy and safety evaluation of a novel hemostatic gelatin matrix for intraoperative hemostasis a prospective randomized controlled trial
url https://doi.org/10.1038/s41598-024-77487-3
work_keys_str_mv AT pengluo efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT qilai efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT lixu efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT zhenzhongchen efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT runshengguo efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT banglinxie efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT pingyi efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT zhiyingyang efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial
AT binzhang efficacyandsafetyevaluationofanovelhemostaticgelatinmatrixforintraoperativehemostasisaprospectiverandomizedcontrolledtrial